Respiratory syncytial virus: an overview DOI
Alaa A. A. Aljabali, Mohammad A. Obeid, Mohamed El‐Tanani

et al.

Future Virology, Journal Year: 2023, Volume and Issue: 18(9), P. 595 - 609

Published: June 1, 2023

Respiratory syncytial virus (RSV) is a leading cause of respiratory illnesses that primarily affects children, particularly those under 2 years old, and adults. RSV infections can lead to hospitalization even mortality. The transmitted through droplets spread by coughing or sneezing. We conducted an extensive literature search focused on RSV, pathogenicity relevant keywords like 'RSV treatment,' vaccine,' diagnosis' explore effective treatment strategies, advances in potential vaccines ongoing clinical trials, progress diagnostic techniques for accurate timely detection infections. These findings are crucial developing appropriate management control measures.

Language: Английский

Performance of clinical metagenomics in France: a prospective observational study DOI Creative Commons
Jacques Fourgeaud, Béatrice Regnault, Vichita Ok

et al.

The Lancet Microbe, Journal Year: 2023, Volume and Issue: 5(1), P. e52 - e61

Published: Dec. 1, 2023

Metagenomic next-generation sequencing (mNGS) allows untargeted identification of a broad range pathogens, including rare or novel microorganisms. Despite the recognition mNGS as valuable diagnostic tool for infections, most relevant indications this innovative strategy remain poorly defined. We aimed to assess determinants positivity and clinical utility mNGS.

Language: Английский

Citations

25
Respiratory syncytial virus infections in adults: a narrative review DOI
Joanne Wildenbeest, David M. Lowe, Joseph F. Standing

et al.

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: 12(10), P. 822 - 836

Published: Sept. 9, 2024

Language: Английский

Citations

12
Recent Advances in Molecular Mechanisms of Nucleoside Antivirals DOI Creative Commons

Polina N. Kamzeeva,

Andrey V. Aralov, Vera A. Alferova

et al.

Current Issues in Molecular Biology, Journal Year: 2023, Volume and Issue: 45(8), P. 6851 - 6879

Published: Aug. 17, 2023

The search for new drugs has been greatly accelerated by the emergence of viruses and drug-resistant strains known pathogens. Nucleoside analogues (NAs) are a prospective class antivirals due to safety profiles, which important rapid repurposing in fight against emerging Recent improvements research methods have revealed unexpected details mechanisms action NAs that can pave way approaches further development effective drugs. This review accounts advanced techniques viral polymerase targeting, host enzyme targeting approaches, prodrug-based strategies antiviral NAs.

Language: Английский

Citations

18
Respiratory Syncytial Virus Infection: Treatments and Clinical Management DOI Creative Commons
Shiza Malik,

Tahir Ahmad,

Khalid Muhammad

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(2), P. 491 - 491

Published: Feb. 20, 2023

Respiratory syncytial virus (RSV) is a major healthcare concern, especially for immune-compromised individuals and infants below 5 years of age. Worldwide, it known to be associated with incidences morbidity mortality in infants. Despite the seriousness issue continuous rigorous scientific efforts, no approved vaccine or available drug fully effective against RSV. The purpose this review article provide insights into past ongoing efforts securing vaccines therapeutics readers will able confer mechanism existing therapies loopholes that need overcome future therapeutic development A methodological approach was applied collect latest data updated results regarding We outline throughput vaccination technologies prophylactic linked range approaches already (with limited use) those undergoing trials are included. Moreover, important regimens used alone conjugation adjuvants also briefly discussed. After reading article, audience understand current standing clinical management form vaccine, prophylactic, candidates An understanding biological behavior acting as reason behind lack RSV developed. literature indicates limitations attached management, drugs, could explained by dealing challenges study designs improvement further work approval on novel applications.

Language: Английский

Citations

12
Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2 DOI

Kiran Shehzadi,

Afsheen Saba,

Mingjia Yu

et al.

Topics in Current Chemistry, Journal Year: 2023, Volume and Issue: 381(5)

Published: June 15, 2023

Language: Английский

Citations

11
Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine DOI Creative Commons
Genaro Hernandez, Adam Osinski, Abir Majumdar

et al.

Journal of Biological Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 108378 - 108378

Published: March 1, 2025

Language: Английский

Citations

0
Regulation of viral RNA-dependent RNA polymerases by phosphorylation DOI Creative Commons

Camille Duflos,

Thomas Michiels

Frontiers in Virology, Journal Year: 2023, Volume and Issue: 3

Published: April 6, 2023

RNA viruses encode an RNA-dependent polymerase (RdRp), which is essential for transcription and replication of their genome since host cells lack equivalent enzymes. RdRp residues were shown to be phosphorylated by kinases in several human, animal or plant including flaviviruses, picornaviruses, coronaviruses, influenza tymoviruses. RdRps can on distinct kinases. Phosphomimetic mutations identified either positively negatively regulate synthesis association with other proteins. Interestingly, some evolved recruit cellular through direct protein-protein interaction, likely promote tightly control own phosphorylation. Given the nature virus replication, a better knowledge RdRps’ phosphorylation expected facilitate design future drugs that strongly affect activity.

Language: Английский

Citations

1
Impact of Treatment of Chronic HCV Patients by Direct Acting Antiviral Drugs (DAADs) on COVID -19 Disease Frequency and Severity DOI Creative Commons

Rasha H Shehata,

Eman Zareh,

Ehab F. Moustafa

et al.

Afro-Egyptian Journal of Infectious and Endemic Diseases, Journal Year: 2023, Volume and Issue: 0(0), P. 0 - 0

Published: Sept. 24, 2023

Background and study aim: Since both SARS-CoV-2 Hepatitis C virus (HCV) are positive-sense RNA viruses, it is logical to consider those nucleotide analogues found be successful against HCV could potentially demonstrate similar efficacy severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The present aims at estimating the frequency severity of COVID-19 in HCV-treated patients. Patients Methods: Cross-sectional was accomplished. enrolled 200 HCV-infected individuals who were eligible for DAADs therapy had received treatment 2019 before pandemic. regimen all patients consisted Sofosbuvir plus Daclatasvir a duration 3 months, except three same 6 months as result liver cirrhosis.‎ Results: attained mean age 53.6 years. Most (74%) came from rural areas, forty-seven (23.5%) different chronic diseases, with hypertension (17.5%) diabetes mellitus (13%) being most common. majority, 183 (91.5%), achieved sustained virological response (SVR). Only 12 (6%) developed COVID-19. In (75%), infection till seroconversion 10 days. All current study, ultimately improved no mortality. Nine (75%) infected one year after last dose DAADs. rarely follow recommended hygienic measures‎. Conclusion recommendations: Previous hepatitis by provides protection SARS-CoV-2. Future large, randomized trials warranted draw firm conclusions.

Language: Английский

Citations

1
One-pot synthesis, characterization and antiviral properties of new benzenesulfonamide-based spirothiazolidinones DOI Creative Commons
Çağla Begüm Apaydın, Lieve Naesens, Gökçe Cihan‐Üstündağ

et al.

Molecular Diversity, Journal Year: 2024, Volume and Issue: 28(4), P. 2681 - 2688

Published: June 27, 2024

A novel series of benzenesulfonamide substituted spirothiazolidinone derivatives (3a-j) were synthesized, characterized and evaluated for their antiviral activity. The spirocyclic compounds prepared by the condensation 4-(aminosulfonyl)-2-methoxybenzohydrazide, appropriate cyclic ketones 2-mercaptopropionic acid in a one-pot reaction. structures new established IR,

Language: Английский

Citations

0
The Impact of SARS-CoV-2 nsp14 Proofreading on Nucleoside Antiviral Activity: Insights from Genetic and Pharmacological Investigations DOI Open Access

Ju-Yi Peng,

Frederick Lahser, Christopher Warren

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: July 25, 2024

Nucleoside analogues are a class of well-established antiviral agents that act by being directly incorporated into the viral genome during replication process, resulting in chain termination or induction lethal mutations. While many nucleoside have exhibited broad-spectrum activity against wide range viruses, their effectiveness SARS-CoV-2 is limited. The lack hypothesized to be attributed proofreading function nsp14 exonuclease. In this study, role modulating was investigated using genetic and pharmacological approaches. Introduction exonuclease attenuation disabling mutations led either severe defect increased sensitivity SARS-CoV replicons specific analogues. contrast, repurposing HCV NS5A inhibitors suppress insufficient enhance potency These findings provided further support for as target development highlighted complex interplay between RNA replication.

Language: Английский

Citations

0